JPMorgan lowered the firm’s price target on Apellis to $64 from $72 and keeps an Overweight rating on the shares. The analyst updated models in the Smid-cap biotechnology space.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis price target raised to $41 from $38 at Wedbush
- Apellis price target raised to $96 from $86 at Baird
- Apellis price target raised to $74 from $66 at Goldman Sachs
- Apellis, Sobi announces Phase 3 VALIANT study met primary endpoint
- Apellis and Sobi announce pegcetacoplan meets Phase 3 primary endpoint